ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections
- PMID: 34003176
- DOI: 10.14309/ajg.0000000000001278
ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections
Erratum in
-
Correction to: ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections.Am J Gastroenterol. 2022 Feb 1;117(2):358. doi: 10.14309/ajg.0000000000001529. Am J Gastroenterol. 2022. PMID: 34658366 No abstract available.
Abstract
Clostridioides difficile infection occurs when the bacterium produces toxin that causes diarrhea and inflammation of the colon. These guidelines indicate the preferred approach to the management of adults with C. difficile infection and represent the official practice recommendations of the American College of Gastroenterology. The scientific evidence for these guidelines was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation process. In instances where the evidence was not appropriate for Grading of Recommendations Assessment, Development, and Evaluation but there was consensus of significant clinical merit, key concept statements were developed using expert consensus. These guidelines are meant to be broadly applicable and should be viewed as the preferred, but not the only, approach to clinical scenarios.
Copyright © 2021 by The American College of Gastroenterology.
Comment in
-
Why Do ACG and AGA Guidelines Differ for the Use of Probiotics and the Prevention of CDI?Am J Gastroenterol. 2022 Mar 1;117(3):501. doi: 10.14309/ajg.0000000000001567. Am J Gastroenterol. 2022. PMID: 35020606 Free PMC article. No abstract available.
-
Response to McFarland et al.Am J Gastroenterol. 2022 Mar 1;117(3):501-502. doi: 10.14309/ajg.0000000000001638. Am J Gastroenterol. 2022. PMID: 35137698 No abstract available.
-
Infection and Inflammation of the Genitourinary Tract.J Urol. 2023 Feb;209(2):428-429. doi: 10.1097/JU.0000000000003041. Epub 2022 Nov 3. J Urol. 2023. PMID: 36326582 No abstract available.
Similar articles
-
Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection.Microbiol Spectr. 2021 Oct 31;9(2):e0079921. doi: 10.1128/Spectrum.00799-21. Epub 2021 Oct 20. Microbiol Spectr. 2021. PMID: 34668727 Free PMC article.
-
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.Drugs. 2022 Oct;82(15):1527-1538. doi: 10.1007/s40265-022-01797-x. Epub 2022 Oct 26. Drugs. 2022. PMID: 36287379 Free PMC article. Clinical Trial.
-
Diagnosis and Treatment of Clostridioides (Clostridium) difficile Infection in Adults in 2020.JAMA. 2020 Apr 14;323(14):1403-1404. doi: 10.1001/jama.2019.3849. JAMA. 2020. PMID: 32150234 Review. No abstract available.
-
Clostridioides difficile from intracardiac vegetation.Anaerobe. 2021 Jun;69:102350. doi: 10.1016/j.anaerobe.2021.102350. Epub 2021 Feb 18. Anaerobe. 2021. PMID: 33610766
-
Recommendations and guidelines for the treatment of Clostridioides difficile infection in Taiwan.J Microbiol Immunol Infect. 2020 Apr;53(2):191-208. doi: 10.1016/j.jmii.2020.02.002. Epub 2020 Feb 14. J Microbiol Immunol Infect. 2020. PMID: 32169531 Review.
Cited by
-
Bioengineered Probiotics for Clostridioides difficile Infection: An Overview of the Challenges and Potential for This New Treatment Approach.Probiotics Antimicrob Proteins. 2024 Nov 12. doi: 10.1007/s12602-024-10398-x. Online ahead of print. Probiotics Antimicrob Proteins. 2024. PMID: 39531149 Review.
-
Clinical Performance of the LiquidArray® Gastrointestinal VER 1.0 Assay in Patients with Suspected Gastroenteritis.Diagnostics (Basel). 2024 Oct 25;14(21):2377. doi: 10.3390/diagnostics14212377. Diagnostics (Basel). 2024. PMID: 39518345 Free PMC article.
-
Comparative effectiveness of treatments for recurrent Clostridioides difficile infection: a network meta-analysis of randomized controlled trials.Front Pharmacol. 2024 Oct 17;15:1430724. doi: 10.3389/fphar.2024.1430724. eCollection 2024. Front Pharmacol. 2024. PMID: 39484168 Free PMC article.
-
Gut Microbiota and New Microbiome-Targeted Drugs for Clostridioides difficile Infections.Antibiotics (Basel). 2024 Oct 20;13(10):995. doi: 10.3390/antibiotics13100995. Antibiotics (Basel). 2024. PMID: 39452261 Free PMC article. Review.
-
Systematic review of the orally administered microbiome therapeutic, fecal microbiota spores, live-brpk, to prevent recurrence of Clostridioides difficile infection in adults.SAGE Open Med. 2024 Oct 9;12:20503121241274192. doi: 10.1177/20503121241274192. eCollection 2024. SAGE Open Med. 2024. PMID: 39386261 Free PMC article. Review.
References
-
- Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108:478–98; quiz 499.
-
- Lawson PA, Citron DM, Tyrrell KL, et al. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prévot 1938. Anaerobe 2016;40:95–9.
-
- McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:e1–48.
-
- Crobach MJ, Planche T, Eckert C, et al. European society of clinical microbiology and infectious diseases: Update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect 2016;22(Suppl 4):S63–81.
-
- Debast SB, Bauer MP, Kuijper EJ, et al. European Society of Clinical Microbiology and Infectious Diseases: Update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014;20(Suppl 2):1–26.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
